Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | VDR | P11473 | 1/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 10/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | CD69 | Q07108 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13580642 | 0.89 | CYP2C19 (0.66) | CYP2C19SMN1; SMN2VDRMRGPRX4PPARD | |
| SCHEMBL13757719 | 0.88 | CYP2C19 (0.74) | CYP2C19SMN1; SMN2PTGDR2HTTKMT2A | |
| SCHEMBL5284414 | 0.85 | PTGDR2 (0.70) | CYP2C19SMN1; SMN2PTGDR2HTTKMT2A | |
| SCHEMBL5321878 | 0.84 | CYP2C19 (0.68) | CYP2C19SMN1; SMN2PPARDPTGDR2PPARG | |
| SCHEMBL4642505 | 0.84 | CYP2C19 (1.00) | CYP2C19SMN1; SMN2PPARDPTGDR2KDM4E | |
| SCHEMBL5320268 | 0.84 | CYP2C19 (0.68) | CYP2C19SMN1; SMN2PTGDR2KDM4EHTT | |
| SCHEMBL13624055 | 0.84 | CYP2C19 (0.68) | CYP2C19SMN1; SMN2PTGDR2HTTKMT2A | |
| SCHEMBL14076372 | 0.84 | CYP2C19 (0.68) | CYP2C19SMN1; SMN2MRGPRX4PTGDR2HTT | |
| SCHEMBL4909292 | 0.84 | CYP2C19 (0.68) | CYP2C19SMN1; SMN2PPARDPTGDR2PPARA | |
| SCHEMBL12213691 | 0.84 | CYP2C19 (0.68) | CYP2C19SMN1; SMN2VDRPPARDPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-09-01 | — | — | US | disclosed |
| US-9382216-B2 | Substituted morpholines as modulators for the calcium sensing receptor | LUPIN LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | CYP2C19 2645/4885SMN1; SMN2 661/4885VDR 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.